Richard Samulski

Viralgen Vector Core SL is a contract development and manufacturing organization (CDMO) that produces AAV gene therapy treatments for pharmaceutical and biotech companies. The company was founded in 2017 by Javier García Cogorro and is based in Donostia-San Sebastian, Spain. Viralgen offers the Pro10™ based suspension manufacturing platform, which increases scalability, performance, and yield of AAV therapies. The Spanish company's clinical facilities have four CGMP manufacturing suites, with 250-liter and 500-liter bioreactors. In 2020, Viralgen expanded within the scientific park by constructing a new building for large-scale commercial manufacturing. The new state-of-the-art space includes three additional CGMP suites with a manufacturing capacity of >2,000 liters each, as well as a suite dedicated to fully automated fill and finish operations. The new facility has received the CGMP certification by the Spanish Agency for Medicines and Medical Devices (AEMPS) as part of the EMA network. The CEO is Jimmy Vanhove.

Asklepios BioPharmaceutical, Inc. operates as a gene therapy-based company. It engages in capsid development, scaled manufacturing, and a portfolio of therapeutic programs. The company was founded by Richard Jude Samulski, Xiao Xiao, and Sheila A. Mikhail in 2001 and is headquartered in Durham, NC.

Viralgen Vector Core SL is a contract development and manufacturing organization (CDMO) that produces AAV gene therapy treatments for pharmaceutical and biotech companies. The company was founded in 2017 by Javier García Cogorro and is based in Donostia-San Sebastian, Spain. Viralgen offers the Pro10™ based suspension manufacturing platform, which increases scalability, performance, and yield of AAV therapies. The Spanish company's clinical facilities have four CGMP manufacturing suites, with 250-liter and 500-liter bioreactors. In 2020, Viralgen expanded within the scientific park by constructing a new building for large-scale commercial manufacturing. The new state-of-the-art space includes three additional CGMP suites with a manufacturing capacity of >2,000 liters each, as well as a suite dedicated to fully automated fill and finish operations. The new facility has received the CGMP certification by the Spanish Agency for Medicines and Medical Devices (AEMPS) as part of the EMA network. The CEO is Jimmy Vanhove.

Asklepios BioPharmaceutical, Inc. operates as a gene therapy-based company. It engages in capsid development, scaled manufacturing, and a portfolio of therapeutic programs. The company was founded by Richard Jude Samulski, Xiao Xiao, and Sheila A. Mikhail in 2001 and is headquartered in Durham, NC.

Asklepios BioPharmaceutical, Inc. operates as a gene therapy-based company. It engages in capsid development, scaled manufacturing, and a portfolio of therapeutic programs. The company was founded by Richard Jude Samulski, Xiao Xiao, and Sheila A. Mikhail in 2001 and is headquartered in Durham, NC.